13-valent pneumococcal conjugate vaccine pcv13 prevenar 13/prevnar 13  (Pfizer Inc)

Journal: Human Vaccines & Immunotherapeutics

Article Title: Pneumococcal serotype prevalence and antibiotic resistance in children in South and Southeast Asia, 2012–2024

doi: 10.1080/21645515.2024.2417554

Figure Lengend Snippet: Serotypes covered by PCV7, PCV10, PCV13, PCV20, and PPSV23.

Article Snippet: Ltd., Pune, India), , the 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar Ⓡ 13, Wyeth Pharmaceuticals Inc, Philadelphia, PA, USA), and the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax Ⓡ 23, Merck & Co Inc, Whitehouse Station, NJ, USA).

Techniques:

Journal: Human Vaccines & Immunotherapeutics

Article Title: Pneumococcal serotype prevalence and antibiotic resistance in children in South and Southeast Asia, 2012–2024

doi: 10.1080/21645515.2024.2417554

Figure Lengend Snippet: Use of pneumococcal vaccines in NIPs.

Article Snippet: Ltd., Pune, India), , the 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar Ⓡ 13, Wyeth Pharmaceuticals Inc, Philadelphia, PA, USA), and the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax Ⓡ 23, Merck & Co Inc, Whitehouse Station, NJ, USA).

Techniques: Vaccines

Journal: Vaccines

Article Title: Mortality of Invasive Pneumococcal Disease following Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Greenland

doi: 10.3390/vaccines12020179

Figure Lengend Snippet: Crude and age-standardized all-cause mortality rates (MR) in Greenland, and crude and age-standardized mortality 31 days after invasive pneumococcal disease (IPD) hospitalization in Greenland for the total period (1995–2020), pre (1995–2010), and post (2010–2020) introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in Greenland.

Article Snippet: The 13-valent pneumococcal conjugate vaccine Prevnar 13 ® (PCV13; Pfizer, New York, NY, USA), covering 13 Streptococcus pneumoniae serotypes was introduced in the childhood vaccination program (CVP) by 1 September 2010, in Greenland [ ].

Techniques:

Journal: Vaccines

Article Title: Mortality of Invasive Pneumococcal Disease following Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Greenland

doi: 10.3390/vaccines12020179

Figure Lengend Snippet: Standardized mortality ratio (SMR) in patients with invasive pneumococcal disease (IPD) per 1000 person-years in Greenland for the total period (1995–2020), pre- (1995–2010), and post- (2010–2020) introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) to the childhood vaccination program in 2010 in Greenland.

Article Snippet: The 13-valent pneumococcal conjugate vaccine Prevnar 13 ® (PCV13; Pfizer, New York, NY, USA), covering 13 Streptococcus pneumoniae serotypes was introduced in the childhood vaccination program (CVP) by 1 September 2010, in Greenland [ ].

Techniques: Isolation

Journal: Mediterranean Journal of Hematology and Infectious Diseases

Article Title: Bacterial Infections Following Splenectomy for Malignant and Nonmalignant Hematologic Diseases

doi: 10.4084/MJHID.2015.057

Figure Lengend Snippet: Dose and time administration of Vaccines.

Article Snippet: – However, in USA, the high rate of invasive pneumococcal diseases (IPD) found through 2010 among adults aged 18–64 years with hematologic cancer induced the Advisory Committee on Immunization Practices (ACIP) on 20 June 2012 to extend routine use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.) to adults aged ≥19 years with functional or anatomic asplenia, other than to other immunocompromised conditions, cerebrospinal fluid (CSF) leaks, or cochlear implants.

Techniques: Infection